Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) Director Sells 10,800 Shares of Stock

Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Troy Edward Wilson sold 10,800 shares of the stock in a transaction on Friday, June 13th. The stock was sold at an average price of $3.40, for a total transaction of $36,720.00. Following the transaction, the director now directly owns 43,550 shares in the company, valued at approximately $148,070. This represents a 19.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Puma Biotechnology Stock Down 0.6%

Shares of PBYI stock traded down $0.02 on Tuesday, hitting $3.43. The stock had a trading volume of 210,811 shares, compared to its average volume of 443,805. The business has a 50 day moving average of $3.20 and a 200 day moving average of $3.12. The stock has a market cap of $170.23 million, a price-to-earnings ratio of 4.45 and a beta of 1.29. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.53 and a quick ratio of 1.43. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $4.13.

Institutional Trading of Puma Biotechnology

A number of large investors have recently added to or reduced their stakes in the stock. Acorn Capital Advisors LLC purchased a new stake in Puma Biotechnology during the fourth quarter worth about $7,475,000. Acadian Asset Management LLC increased its holdings in Puma Biotechnology by 1.8% during the first quarter. Acadian Asset Management LLC now owns 2,008,146 shares of the biopharmaceutical company's stock worth $5,940,000 after buying an additional 36,018 shares during the last quarter. American Century Companies Inc. increased its holdings in Puma Biotechnology by 21.2% during the first quarter. American Century Companies Inc. now owns 1,149,660 shares of the biopharmaceutical company's stock worth $3,403,000 after buying an additional 201,284 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Puma Biotechnology by 24.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 863,760 shares of the biopharmaceutical company's stock worth $2,635,000 after buying an additional 170,968 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its holdings in Puma Biotechnology by 70.6% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 831,689 shares of the biopharmaceutical company's stock worth $2,462,000 after buying an additional 344,321 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a report on Friday, February 28th. Wall Street Zen upgraded shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 22nd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.